Nodular lymphocyte predominant Hodgkin lymphoma: Advances in disease biology, risk stratification and treatment

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Practical management of chronic lymphocytic leukemia with acalabrutinib

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse

Therapeutic Options for Relapsed/Refractory Mantle Cell Lymphoma

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies